Aankondiging • May 07
SelectQuote, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2026 SelectQuote, Inc. reaffirmed earnings guidance for the Fiscal Year 2026. For the year, the company's revenue is expected to be in a range of $1.61 billion to $1.71 billion. Aankondiging • Apr 21
SelectQuote, Inc. to Report Q3, 2026 Results on May 05, 2026 SelectQuote, Inc. announced that they will report Q3, 2026 results Pre-Market on May 05, 2026 Aankondiging • Mar 26
SelectQuote, Inc. Receives Notice of Non-Compliance with NYSE Listing Standard On March 19, 2026, SelectQuote, Inc. (the Company) received a notice (the Notice) from the New York Stock Exchange (the NYSE) indicating that the Company is no longer in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's common stock was less than $1.00 per share over a consecutive 30 trading-day period. The Company will notify the NYSE of its intent to cure the stock price deficiency and return to compliance with the continued listing standard. The Company can regain compliance at any time within the six-month cure period following receipt of the Notice if, on the last trading day of any calendar month during the cure period, the Company's common stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. The Company intends to closely monitor its stock price during the cure period and will, if necessary, consider available alternatives to cure the stock price deficiency. If the Company determines that curing the deficiency will require taking action that must be approved by the Company's stockholders, the price condition will be deemed cured if the price of the Company's common stock promptly exceeds $1.00 per share following such action and remains above that level for at least the following 30 trading days. The Company's common stock will continue to be listed and traded on the NYSE during the cure period, subject to the Company's compliance with other NYSE continued listing standards. Aankondiging • Mar 17
SelectQuote, Inc. Announces SelectQuote Local Franchise Model SelectQuote, Inc. announced an initiative to expand its reach and complement its existing, telephonic insurance distribution model. SelectQuote Local will leverage the Company’s marketing, technology, customer service, and carrier relationships to offer consumers its senior health and life insurance products through a franchise model offering local sales and support. SelectQuote Local provides consumers the opportunity to meet with local representatives while still offering the Company’s same affordable and simple way to quickly and easily find the type of insurance to meet their unique needs. Franchise owners will have an opportunity to purchase rights to operate their SelectQuote Local franchise in a particular geographic region, providing a business opportunity for them and a new growth opportunity for the Company. Aankondiging • Feb 05
SelectQuote, Inc. Provides Earnings Guidance for the Fiscal Year 2026 SelectQuote, Inc. provided earnings guidance for the fiscal year 2026. For the year, the company revenue expected in a range of $1.61 billion to $1.71 billion. Aankondiging • Jan 22
SelectQuote, Inc. to Report Q2, 2026 Results on Feb 05, 2026 SelectQuote, Inc. announced that they will report Q2, 2026 results Pre-Market on Feb 05, 2026 Aankondiging • Oct 23
SelectQuote, Inc. to Report Q1, 2026 Results on Nov 06, 2025 SelectQuote, Inc. announced that they will report Q1, 2026 results Pre-Market on Nov 06, 2025 Aankondiging • Oct 03
SelectQuote, Inc., Annual General Meeting, Nov 11, 2025 SelectQuote, Inc., Annual General Meeting, Nov 11, 2025. Aankondiging • Aug 07
SelectQuote, Inc. to Report Q4, 2025 Results on Aug 21, 2025 SelectQuote, Inc. announced that they will report Q4, 2025 results Pre-Market on Aug 21, 2025 Aankondiging • Jul 17
SelectQuote, Inc. Unveils New Program Designed to Elevate Health Plan Performance by Improving Medication Adherence for Polychronic Medicare Beneficiaries SelectQuote, Inc. announced the expanded launch of their innovative concierge-like service designed to specifically improve medication adherence for Medicare beneficiaries managing multiple chronic conditions and complex medication regimens. SelectQuote's SelectRx pharmacy recently trialed a new approach with a regional health plan that demonstrated over 90% adherence, strengthening HEDIS Star ratings across the triple-weighted cholesterol, diabetes and hypertension measures. The Company plans to expand to additional payers this calendar year and will roll out across SelectRx's pharmacy platform in 2026. This program further demonstrates SelectQuote's deep commitment to driving better health outcomes and greater value for both patients and payer partners. This high-touch solution is purpose-built to address the critical challenge of medication non-adherence, which often leads to preventable hospitalizations, adverse drug interactions, and escalating healthcare costs for the Medicare system. SelectQuote aims to help patients overcome adherence barriers through escalations to its clinical pharmacist team, who can provide specialized intervention. The Company also plans to launch a complementary program for lower risk members to support their continued medication adherence. Aankondiging • Jul 03
SelectQuote, Inc. Announces Demise of Tom Grant, Vice Chairman of the Board of Directors, on July 1, 2025 SelectQuote, Inc. announced that William Thomas (Tom) Grant II, Vice Chairman and former President of company, passed away on July 1, 2025, following a battle with cancer. Tom was instrumental in formulating and executing company's strategy over the past fifteen years as the business evolved from a term life insurance brokerage into a diversified insurance and rapidly-growing healthcare services business. His strategic insights and dedication were pivotal to the company’s success. Tom also personally touched the lives of thousands of company associates and their families with his wit, warmth, and ever-present smile. Aankondiging • May 12
SelectQuote, Inc. Provides Earnings Guidance for the Year Ending June 30, 2025 SelectQuote, Inc. provided earnings guidance for the year ending June 30, 2025. For the year, the company expects revenue to be in the range of $1.500 billion to $1.575 billion and net income to be in the range of negative $1,000,000 to positive $28,000,000. Aankondiging • May 05
SelectQuote, Inc. to Report Q3, 2025 Results on May 12, 2025 SelectQuote, Inc. announced that they will report Q3, 2025 results on May 12, 2025 Aankondiging • Mar 01
SelectQuote, Inc. announced that it has received $350 million in funding from Bain Capital, LP, Morgan Stanley, Investment Arm, Newlight Partners LP On February 28, 2025. SelectQuote, Inc. has closed the transaction. it has issued 350,000 shares of Senior Non-Convertible Preferred Stock at a price of $1,000 per share for proceeds of $350,000,000 and 30,833,333 warrants to purchase shares of the Company’s common stock. Aankondiging • Feb 12
SelectQuote, Inc. announced that it expects to receive $350 million in funding from Bain Capital, LP, Morgan Stanley, Investment Arm, Newlight Partners LP SelectQuote, Inc. announced that it has entered into agreement with Bain Capital, Morgan Stanley Private Credit, and Newlight Partners for gross proceeds of $350 million on February 10, 2025. Additionally, SelectQuote is appointing Chris Wolfe of Bain Capital and Srdjan Vukovic of Newlight Partners to the Board of Directors, each bringing over 20 years of investing and healthcare sector experience to the Company. SelectQuote anticipates Mr. Wolfe and Mr. Vukovic will join the Board upon the closing of the transaction, expected to be on February 28, 2025. Aankondiging • Feb 11
SelectQuote, Inc. Provides Earnings Guidance for the Fiscal Year Ending June 30, 2025 SelectQuote, Inc. provided earnings guidance for the fiscal year ending June 30, 2025. For the period, the company's Revenue is expected in a range of $1.500 billion to $1.575 billion. Net loss expected in a range of $24 million to Net income of $11 million. Aankondiging • Feb 04
SelectQuote, Inc. to Report Q2, 2025 Results on Feb 10, 2025 SelectQuote, Inc. announced that they will report Q2, 2025 results After-Market on Feb 10, 2025 Aankondiging • Nov 05
SelectQuote, Inc. Provides Unaudited Earnings Guidance for the Fiscal Year Ending June 30, 2025 SelectQuote, Inc. provided unaudited earnings guidance for the fiscal year ending June 30, 2025. For the year, the company expects revenue to be in a range of $1.425 billion to $1.525 billion. Net income to be in a range of negative 59 million to $3 million. Reported Earnings • Nov 05
First quarter 2025 earnings released: US$0.26 loss per share (vs US$0.18 loss in 1Q 2024) First quarter 2025 results: US$0.26 loss per share (further deteriorated from US$0.18 loss in 1Q 2024). Revenue: US$292.3m (up 26% from 1Q 2024). Net loss: US$44.5m (loss widened 44% from 1Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 4.9% growth forecast for the Insurance industry in Europe. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. New Risk • Oct 29
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$34m Forecast net loss in 2 years: US$1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$1.4m net loss in 2 years). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Aankondiging • Oct 23
SelectQuote, Inc. to Report Q1, 2025 Results on Nov 04, 2024 SelectQuote, Inc. announced that they will report Q1, 2025 results Pre-Market on Nov 04, 2024 Aankondiging • Oct 03
SelectQuote, Inc., Annual General Meeting, Nov 12, 2024 SelectQuote, Inc., Annual General Meeting, Nov 12, 2024. New Risk • Sep 15
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Reported Earnings • Sep 14
Full year 2024 earnings released: US$0.20 loss per share (vs US$0.35 loss in FY 2023) Full year 2024 results: US$0.20 loss per share (improved from US$0.35 loss in FY 2023). Revenue: US$1.32b (up 32% from FY 2023). Net loss: US$34.1m (loss narrowed 42% from FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Insurance industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings. Aankondiging • Sep 13
SelectQuote, Inc. Provides Earnings Guidance for the Fiscal Year 2025 SelectQuote, Inc. provided earnings guidance for the fiscal year 2025. For the year, the company expects Revenue in a range of $1.4 billion to $1.5 billion. Net loss expected in a range of $42 million to $6 million. Aankondiging • Sep 11
SelectQuote, Inc. to Report Q4, 2024 Results on Sep 13, 2024 SelectQuote, Inc. announced that they will report Q4, 2024 results Pre-Market on Sep 13, 2024 Aankondiging • May 10
SelectQuote, Inc. Raises Earnings Guidance for the Fiscal Year 2024 SelectQuote, Inc. raised earnings guidance for the fiscal year 2024. For the year, the company's revenue expected in a range of $1.25 billion to $1.3 billion vs prior range of $1.23 billion to $1.3 billion. Net loss expected in a range of $34 million to $21 million vs prior range of $45 million to $22 million. Reported Earnings • May 09
Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.056 in 3Q 2023) Third quarter 2024 results: EPS: US$0.051 (down from US$0.056 in 3Q 2023). Revenue: US$376.4m (up 26% from 3Q 2023). Net income: US$8.55m (down 7.7% from 3Q 2023). Profit margin: 2.3% (down from 3.1% in 3Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Insurance industry in Europe. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Aankondiging • May 03
SelectQuote, Inc. to Report Q3, 2024 Results on May 09, 2024 SelectQuote, Inc. announced that they will report Q3, 2024 results Pre-Market on May 09, 2024 New Risk • Feb 29
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$50m Forecast net loss in 2 years: US$1.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$3.6m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$1.8m net loss in 2 years). Share price has been volatile over the past 3 months (9.2% average weekly change). Reported Earnings • Feb 08
Second quarter 2024 earnings released: EPS: US$0.12 (vs US$0.14 in 2Q 2023) Second quarter 2024 results: EPS: US$0.12 (down from US$0.14 in 2Q 2023). Revenue: US$405.4m (up 27% from 2Q 2023). Net income: US$19.4m (down 14% from 2Q 2023). Profit margin: 4.8% (down from 7.1% in 2Q 2023). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Insurance industry in Germany. Aankondiging • Feb 08
SelectQuote, Inc. Revises Earnings Guidance for the Fiscal Year 2024 SelectQuote, Inc. revised earnings guidance for the Fiscal Year 2024. For the year, company expects Revenue in a range of $1.23 billion to $1.3 billion vs prior range of $1.05 billion to $1.2 billion and Net loss expected in a range of $45 million to $22 million vs prior range of $50 million to $22 million. Aankondiging • Jan 24
SelectQuote, Inc. to Report Q2, 2024 Results on Feb 07, 2024 SelectQuote, Inc. announced that they will report Q2, 2024 results Pre-Market on Feb 07, 2024 Aankondiging • Nov 03
SelectQuote, Inc. Provides Earnings Guidance for the Fiscal Year 2024 SelectQuote, Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenue of $232.7 million and net loss of $31.1 million. Reported Earnings • Nov 03
First quarter 2024 earnings released: US$0.18 loss per share (vs US$0.26 loss in 1Q 2023) First quarter 2024 results: US$0.18 loss per share (improved from US$0.26 loss in 1Q 2023). Revenue: US$232.7m (up 43% from 1Q 2023). Net loss: US$31.1m (loss narrowed 27% from 1Q 2023). Revenue is forecast to grow 8.9% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Insurance industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 6 percentage points per year, which is a significant difference in performance. Aankondiging • Oct 26
SelectQuote, Inc. to Report Q1, 2024 Results on Nov 02, 2023 SelectQuote, Inc. announced that they will report Q1, 2024 results After-Market on Nov 02, 2023 Aankondiging • Oct 05
SelectQuote, Inc., Annual General Meeting, Nov 14, 2023 SelectQuote, Inc., Annual General Meeting, Nov 14, 2023, at 09:00 Central Standard Time. Agenda: To consider the election of two Class I directors named in proxy statement to serve until the 2026 annual meeting of stockholders or until their successors are duly elected and qualified; to consider a proposal to ratify the appointment of Deloitte & Touche LLP as company's independent registered public accounting firm for company's fiscal year ending June 30, 2024; to consider a proposal to approve, by non-binding advisory vote, the compensation of company's named executive officers; and to consider any other business as may properly come before the Annual Meeting. New Risk • Sep 24
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$59m Forecast net loss in 2 years: US$21m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$21m net loss in 2 years). Recent Insider Transactions • Sep 19
President of SelectQuote Senior recently bought €106k worth of stock On the 18th of September, Joshua Matthews bought around 98k shares on-market at roughly €1.09 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €1.2m more in shares than they have sold in the last 12 months. New Risk • Sep 14
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$59m Forecast net loss in 2 years: US$1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$1.4m net loss in 2 years). Reported Earnings • Sep 14
Full year 2023 earnings released: US$0.35 loss per share (vs US$1.81 loss in FY 2022) Full year 2023 results: US$0.35 loss per share (improved from US$1.81 loss in FY 2022). Revenue: US$1.00b (up 31% from FY 2022). Net loss: US$58.5m (loss narrowed 80% from FY 2022). Revenue is forecast to grow 8.8% p.a. on average during the next 2 years, compared to a 2.6% growth forecast for the Insurance industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 9 percentage points per year, which is a significant difference in performance. Aankondiging • Aug 24
SelectQuote, Inc. to Report Q4, 2023 Results on Sep 13, 2023 SelectQuote, Inc. announced that they will report Q4, 2023 results Pre-Market on Sep 13, 2023 Recent Insider Transactions • May 18
Vice Chairman recently bought €501k worth of stock On the 16th of May, William Grant bought around 425k shares on-market at roughly €1.18 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was William's only on-market trade for the last 12 months. Aankondiging • May 13
SelectQuote, Inc. Updates Consolidated Earnings Guidance for the Fiscal Year 2023 SelectQuote, Inc. updated consolidated earnings guidance for the fiscal year 2023. For the period, the company expected revenue in a range of $950 million to $970 million. Net loss now expected in a range of $73 million to $55 million. Aankondiging • May 12
SelectQuote, Inc. Provides Consolidated Earnings Guidance for the Third Quarter and Full Year of Fiscal 2023 SelectQuote, Inc. provided consolidated earnings guidance for the third quarter and full year of fiscal 2023. For the quarter, the company expects revenue of $299.4 million. Net income of $9.3 million.For the full year, the company expects revenue now expected in a range of $950 million to $970 million. Net loss now expected in a range of $68 million to $48 million. Reported Earnings • May 11
Third quarter 2023 earnings released: EPS: US$0.056 (vs US$0.039 loss in 3Q 2022) Third quarter 2023 results: EPS: US$0.056 (up from US$0.039 loss in 3Q 2022). Revenue: US$299.4m (up 8.8% from 3Q 2022). Net income: US$9.26m (up US$15.7m from 3Q 2022). Profit margin: 3.1% (up from net loss in 3Q 2022). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Insurance industry in Germany. Aankondiging • Feb 08
SelectQuote, Inc. Provides Earnings Guidance for the Fiscal Year 2023 SelectQuote, Inc. provides earnings guidance for the fiscal year 2023. The company now expects revenue in a range of $910 million to $960 million. Net loss now expected in a range of $94 million to $78 million. Reported Earnings • Feb 08
Second quarter 2023 earnings released: EPS: US$0.14 (vs US$0.84 loss in 2Q 2022) Second quarter 2023 results: EPS: US$0.14 (up from US$0.84 loss in 2Q 2022). Revenue: US$319.2m (up 64% from 2Q 2022). Net income: US$22.5m (up US$159.5m from 2Q 2022). Profit margin: 7.1% (up from net loss in 2Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Insurance industry in Germany. Aankondiging • Jan 20
SelectQuote, Inc. to Report Q2, 2023 Results on Feb 07, 2023 SelectQuote, Inc. announced that they will report Q2, 2023 results Pre-Market on Feb 07, 2023 Board Change • Nov 16
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 1 experienced director. 3 highly experienced directors. Vice Chairman Tom Grant is the most experienced director on the board, commencing their role in 2009. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Nov 04
First quarter 2023 earnings released: US$0.26 loss per share (vs US$0.29 loss in 1Q 2022) First quarter 2023 results: US$0.26 loss per share (improved from US$0.29 loss in 1Q 2022). Revenue: US$162.5m (up 3.1% from 1Q 2022). Net loss: US$42.5m (loss narrowed 9.9% from 1Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Insurance industry in Germany. Aankondiging • Nov 04
Selectquote, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2023 SelectQuote, Inc. reaffirmed earnings guidance for the Fiscal Year 2023. For the year, the company's Revenue expected in a range of $850 million to $950 million and net loss expected in a range of $113 million to $89 million. Aankondiging • Oct 27
SelectQuote Announces Receipt of Continued Listing Standard Notice from NYSE SelectQuote, Inc. (the “Company”) announced that it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating that the Company is no longer in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period. The Company will notify the NYSE of its intent to cure the stock price deficiency and return to compliance with the continued listing standard. The Company can regain compliance at any time within the six-month cure period following receipt of the Notice if, on the last trading day of any calendar month during the cure period, the Company’s common stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. The Company intends to closely monitor its stock price during the cure period and will, if necessary, consider available alternatives to cure the stock price non-compliance. Aankondiging • Oct 15
SelectQuote, Inc. to Report Q1, 2023 Results on Nov 03, 2022 SelectQuote, Inc. announced that they will report Q1, 2023 results Pre-Market on Nov 03, 2022 Aankondiging • Oct 07
SelectQuote, Inc., Annual General Meeting, Nov 15, 2022 SelectQuote, Inc., Annual General Meeting, Nov 15, 2022, at 09:00 Central Standard Time. Agenda: To consider the election of three Class III directors named in this proxy statement to serve until the 2025 annual meeting of stockholders or until their successors are duly elected and qualified; to ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending June 30, 2023; to approve, by non-binding advisory vote, the Company’s executive compensation program; and to transact other business. Reported Earnings • Aug 30
Full year 2022 earnings released: US$1.81 loss per share (vs US$0.81 profit in FY 2021) Full year 2022 results: US$1.81 loss per share (down from US$0.81 profit in FY 2021). Revenue: US$764.0m (down 19% from FY 2021). Net loss: US$297.5m (down 327% from profit in FY 2021). Over the next year, revenue is forecast to grow 19%, compared to a 27% growth forecast for the Insurance industry in Germany. Aankondiging • Aug 30
Selectquote, Inc. Reports Unaudited Consolidated Impairment for the Three Months Ended June 30, 2022 SelectQuote, Inc. reported unaudited consolidated impairment for the three months ended June 30, 2022. For the quarter, the company reported Goodwill impairment of $44,596,000. Impairment of long-lived assets is $3,147,000. Aankondiging • Aug 26
SelectQuote, Inc. Appoints Alan Muney as Chief Medical Officer SelectQuote, Inc. has hired Alan Muney, MD, as part-time Chief Medical Officer. Dr. Muney will focus on healthcare strategy solutions for SelectQuote healthcare services, which encompasses Population Health and SelectRx, bringing extensive experience operating clinical strategy within a national Medicare Advantage health plan and large provider groups. Dr. Muney will provide strategic guidance on program development and execution for health plan initiatives focusing on member engagement, clinical quality, and care delivery. He will also drive initiatives that support healthcare services members in accessing high-value medical and clinical services to achieve improved health outcomes. Dr. Muney is a physician and executive leader with more than 35 years of experience leading healthcare payor and provider organizations. Most recently, he served as Cigna's Chief Medical Officer and EVP of Total Health and Network, overseeing clinical strategy, coverage policy, quality measurement and improvement, and total health physician and clinical operations. Before Cigna, Dr. Muney was an Executive Director in the Private Equity Group at Blackstone and the CEO of Equity Healthcare, which he founded to manage the healthcare costs of Blackstone's portfolio companies. Alan was also EVP, Chief Medical Officer of Oxford Health Plans, and Chief Medical Officer of UnitedHealthcare of the Northeast region from 1998-2007. Aankondiging • Jul 28
SelectQuote, Inc. to Report Q4, 2022 Results on Aug 18, 2022 SelectQuote, Inc. announced that they will report Q4, 2022 results Pre-Market on Aug 18, 2022 Aankondiging • Jun 26
SelectQuote, Inc.(NYSE:SLQT) dropped from Russell 2000 Growth Index SelectQuote, Inc.(NYSE:SLQT) dropped from Russell 2000 Growth Index Aankondiging • May 20
Selectquote, Inc. Announces CFO Changes SelectQuote, Inc. announced the departure of Chief Financial Officer Raff Sadun after 5 years at SelectQuote to pursue a new opportunity outside of the industry. The Board of Directors approved the appointment of Ryan Clement, SVP of Financial Planning & Analysis, as interim CFO effective upon Sadun’s departure at the end of the month. Prior to joining SelectQuote, Clement served as the CFO of a software technology company and has over a decade of experience in senior-level finance and operations roles. Clement will continue to lead SelectQuote’s Financial Planning & Analysis organization while acting as interim CFO. The company’s financial reporting and accounting functions will be led by Stephanie Fisher, SelectQuote’s Chief Accounting Officer, who will assume the role of principal accounting officer effective upon Sadun’s departure. The company has initiated a national search for a permanent Chief Financial Officer. Reported Earnings • May 09
Third quarter 2022 earnings released: US$0.039 loss per share (vs US$0.22 profit in 3Q 2021) Third quarter 2022 results: US$0.039 loss per share (down from US$0.22 profit in 3Q 2021). Revenue: US$275.1m (up 3.7% from 3Q 2021). Net loss: US$6.45m (down 118% from profit in 3Q 2021). Over the next year, revenue is forecast to grow 9.7%, compared to a 19% growth forecast for the industry in Germany. Board Change • May 09
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 1 experienced director. 3 highly experienced directors. Vice Chairman Tom Grant is the most experienced director on the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Aankondiging • May 06
Selectquote, Inc. Provides Earnings Guidance for the Year Ending June 30, 2022 SelectQuote, Inc. provided earnings guidance for the year ending June 30, 2022. For the period, the company's Revenue expected in a range of $810 million to $850 million. Net Loss expected in a range of $255 million to $236 million. Aankondiging • Apr 26
SelectQuote, Inc. to Report Q3, 2022 Results on May 05, 2022 SelectQuote, Inc. announced that they will report Q3, 2022 results Pre-Market on May 05, 2022 Aankondiging • Mar 03
Selectquote, Inc. Introduces Healthcare Advisory Board SelectQuote, Inc. announced the formation of a Healthcare Advisory Board to help the company strengthen the mission and clinical strategy of Population Health. This group of world-class experts will advise Population Health on ways to empower, engage and educate consumers on healthcare solutions and benefits, equipping them to lead healthier lives through improved health outcomes while reducing costs for patients and the healthcare system. This group of world-renowned leaders brings comprehensive healthcare expertise from the pharmaceutical, health IT, payer, provider, and regulatory market segments and will provide important insight and expertise to help shape continuing innovation and growth at Population Health. The Advisory Board will be led by SelectQuote Board members Kavita Patel, MD and Earl “Trace” Devanny. Advisory Board members include: Basit Chaudhry, MD is an internal medicine physician and medical technologist who founded Tuple Health in 2013. His expertise spans healthcare payment, clinical service redesign, and the use of data analytics to improve clinical and financial performance in healthcare. Alan Muney, MD is currently an external advisor to Bain & Company, and a Senior Advisor for Pritzker Private Capital, NEA and Arsenal Capital Partners. From 2010 to 2018, he was the Executive Vice President and Chief Medical Officer for Cigna, leading the company’s health management and network contracting activities. Joe Grogan is a former Assistant to the President, Director of the Domestic Policy Council and Associate Director, Health Programs for the Office of Management and Budget. He is currently a Fellow with the USC Schaeffer Center. He has served at senior management roles at Amgen, Inc., and Gilead Sciences, Inc., and he has an extensive background working with the FDA on regulatory, legislative and policy initiatives. Rebekah Gee, MD is the President and Founder of Nest Health and CEO of Healthcare Services for LSU Health. She formerly served as Secretary of the Louisiana Department of Health, the state’s large agency. She is a policy expert and is widely published in health services research, and has served in numerous additional state and national policy roles. Dr. Patel is currently a Fellow with the Brookings Institute and served in the Obama Administration as Director of Policy for the Office of Intergovernmental Affairs and Public Engagement. She is also an advisor to the Bipartisan Policy Center and a member of Health and Human Services Physician Focused Payment Model Technical Advisory Committee. Devanny is the former CEO of Tract Manager, a provider of healthcare strategic sourcing and compliance application suites. From 2014 to 2016, he served as President of Nuance Communications’ healthcare business. He has also led healthcare company Trizetto Corporation and health information technology company Cerner Corporation. Aankondiging • Feb 10
SelectQuote, Inc. announced delayed 10-Q filing On 02/09/2022, SelectQuote, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Buying Opportunity • Feb 09
Now 43% undervalued after recent price drop Over the last 90 days, the stock is down 67%. The fair value is estimated to be US$5.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.9% over the last year. The company became loss making over the last year. Reported Earnings • Feb 08
Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint Second quarter 2022 results: US$0.84 loss per share (down from US$0.56 profit in 2Q 2021). Revenue: US$195.0m (down 46% from 2Q 2021). Net loss: US$137.0m (down 252% from profit in 2Q 2021). Revenue missed analyst estimates by 57%. Over the next year, revenue is forecast to grow 83%, compared to a 15% growth forecast for the industry in Germany. Aankondiging • Feb 08
SelectQuote, Inc. Provides Earnings Guidance for the Full Year of Fiscal 2022 SelectQuote, Inc. provided earnings guidance for the full year of fiscal 2022. For the full year, the company expects revenue in a range of $810 million to $850 million and net Loss in a range of $255 million to $236 million. Reported Earnings • Nov 05
First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.005 profit in 1Q 2021) The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: US$159.9m (up 29% from 1Q 2021). Net loss: US$45.4m (down US$46.2m from profit in 1Q 2021). Recent Insider Transactions • Sep 12
Vice Chairman recently bought €1.5m worth of stock On the 10th of September, William Grant bought around 145k shares on-market at roughly €10.50 per share. In the last 3 months, they made an even bigger purchase worth €1.7m. This was William's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Sep 03
Investor sentiment improved over the past week After last week's 38% share price gain to €9.37, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 10x in the Insurance industry in Germany. Total loss to shareholders of 44% over the past year. Recent Insider Transactions • Sep 01
Chief Operating Officer recently bought €1.7m worth of stock On the 30th of August, William Grant bought around 230k shares on-market at roughly €7.50 per share. This was the largest purchase by an insider in the last 3 months. This was William's only on-market trade for the last 12 months. Aankondiging • Aug 28
SelectQuote, Inc. Provides Earnings Guidance for the Fiscal Year 2022 SelectQuote, Inc. provided earnings guidance for the fiscal year 2022. For the period, The company expects revenue to be in the range of $1.25 billion and $1.4 billion, which would represent revenue growth of 33% and 49% year-over-year. Reported Earnings • Aug 26
Full year 2021 earnings released: EPS US$0.81 (vs US$0.16 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$937.8m (up 76% from FY 2020). Net income: US$131.0m (up US$147.1m from FY 2020). Profit margin: 14% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Aankondiging • Aug 19
Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against SelectQuote, Inc Glancy Prongay & Murray LLP (‘GPM’) announced that it has filed a class action lawsuit in the United States District Court for the Southern District of New York captioned Hartel v.SelectQuote, Inc., et al., (Case No. 21-cv-06903) on behalf of persons and entities that purchased or otherwise acquired SelectQuote, Inc. (‘SelectQuote’ or ‘the Company’) securities between February 8, 2021 and May 11, 2021, inclusive (the ‘Class Period’). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the ‘Exchange Act’). Investors are hereby notified that they have 60 days from this notice to move the Court to serve as lead plaintiff in this action. On May 11, 2021, SelectQuote held a conference call in connection with its third quarter 2021 financial results during which it disclosed that its fourth quarter results would be impacted by a ‘negative cohort and tail adjustment’ due to ‘lower second-term persistency for the 2019 cohort.’ On this news, the Company’s share price fell $5.50, or 20%, to close at $21.90 per share on May 12, 2021, on unusually heavy trading volume. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made material misrepresentations concerning the following: (1) that SelectQuote’s 2019 cohort was underperforming; (2) that, as a result, the Company’s financial results would be adversely impacted; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Valuation Update With 7 Day Price Move • Aug 14
Investor sentiment deteriorated over the past week After last week's 23% share price decline to US$11.74, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 10x in the Insurance industry in Germany. Total loss to shareholders of 32% over the past year. Reported Earnings • May 13
Third quarter 2021 earnings released: EPS US$0.22 (vs US$0.23 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: US$266.9m (up 80% from 3Q 2020). Net income: US$36.5m (up 76% from 3Q 2020). Profit margin: 14% (in line with 3Q 2020). Aankondiging • May 12
SelectQuote, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending June 30, 2021 SelectQuote, Inc. provided consolidated earnings guidance for the full year ending June 30, 2021. For the year, the company expects revenue to be in the range of $920 million to $940 million and net income to be in the range of $130 million to $138 million. Aankondiging • May 04
SelectQuote, Inc. (NYSE:SLQT) acquired Express Med Pharmaceuticals, Inc. SelectQuote, Inc. (NYSE:SLQT) acquired Express Med Pharmaceuticals, Inc. on May 3, 2021. MyMedPak will be branded as SelectRx.
SelectQuote, Inc. (NYSE:SLQT) completed the acquisition of Express Med Pharmaceuticals, Inc. on May 3, 2021. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment deteriorated over the past week After last week's 16% share price decline to US$22.20, the stock is trading at a trailing P/E ratio of 27.3x, down from the previous P/E ratio of 32.5x. This compares to an average P/E of 13x in the Insurance industry in Germany. Aankondiging • Mar 05
SelectQuote, Inc. has completed a Follow-on Equity Offering in the amount of $291.5 million. SelectQuote, Inc. has completed a Follow-on Equity Offering in the amount of $291.5 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 10,600,000
Price\Range: $27.5 Is New 90 Day High Low • Mar 01
New 90-day high: €26.40 The company is up 51% from its price of €17.50 on 01 December 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Insurance industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €30.90 per share. Aankondiging • Feb 19
SelectQuote, Inc. Appoints Heidy Robertson-Cooper as Vice President, Healthcare Strategy SelectQuote, Inc. has hired Heidy Robertson-Cooper as Vice President, HealthCare Strategy. Robertson-Cooper is a skilled and experienced healthcare leader, spending her career focusing on healthcare policy, value-based payment and delivery system redesign. Most recently, Robertson-Cooper was with the American Academy of Family Physicians as the Division Director, Practice Advancement, where she led strategic planning, execution and operations for four business units. She has also worked with the Missouri Primary Care Association, MissouriHealth+, the Northeast Missouri Health Council and the Sargent Shriver National Center on Poverty Law. Reported Earnings • Feb 10
Second quarter 2021 earnings released: EPS US$0.56 (vs US$0.56 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$358.3m (up 103% from 2Q 2020). Net income: US$90.4m (up US$140.7m from 2Q 2020). Profit margin: 25% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Analyst Estimate Surprise Post Earnings • Feb 10
Revenue beats expectations Revenue exceeded analyst estimates by 13%. Over the next year, revenue is forecast to grow 42%, compared to a 15% growth forecast for the Insurance industry in Germany. Is New 90 Day High Low • Feb 10
New 90-day high: €22.00 The company is up 22% from its price of €18.00 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Insurance industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €30.24 per share. Aankondiging • Jan 24
SelectQuote, Inc. Hires Scott Dikeman to Health Care Business SelectQuote, Inc. announced the hiring of Scott Dikeman. Dikeman recently joined SelectQuote as the Vice President, Strategic Accounts, where he will work on emerging B2B opportunities in health care. He comes to SelectQuote from Cerner. Is New 90 Day High Low • Jan 20
New 90-day high: €20.60 The company is up 32% from its price of €15.60 on 22 October 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Insurance industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.87 per share.